Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mangafodipir - Egetis Therapeutics

Drug Profile

Mangafodipir - Egetis Therapeutics

Alternative Names: mangafodipir trisodium; MnDPDP; PP-099; S 095; Teslascan; WIN 59010

Latest Information Update: 12 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare
  • Developer GE Healthcare; PledPharma
  • Class Acetates; Anti-ischaemics; Contrast media; Ethylenediamines; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents; Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Liver disorders
  • Discontinued Myocardial infarction; Neutropenia

Most Recent Events

  • 17 Dec 2020 PledPharma is now called Egetis Therapeutics
  • 29 Feb 2016 PledPharm receives patent for PLED compounds for their anti-cancer effect by the European Patent Office
  • 29 Feb 2016 PledPharm receives use patent for PLED compounds by authorities in Canada, Russia, Mexico, Japan and Australia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top